Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Question
Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Direct answer
Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints. — bullish pressure on VRTX.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-24
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial”, revision 1, evidence through 2026-09-24. https://marketontology.com/catalysts/2026-09-24/vertex-inaxaplin-phase-iib-cuts-proteinuria-in-kidney-disease-trial-805173
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| VRTX | ▲Bull | 1–5 days | Policy Shift | 63 |
Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints. — bullish pressure on VRTX.
Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.
- SummaryVertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 522.38 2026-09-24 | +0.73% | -2.99% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.